Cargando…

Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas

INTRODUCTION: The tight junction molecule Claudin 18.2 is selectively expressed in healthy and malignant gastric epithelial tissue and is a promising therapy target for high Claudin 18.2 expressing adenocarcinomas of the esophagogastric junction and stomach (AEG/S). METHODS: This study analyzed the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arnold, A., Daum, S., von Winterfeld, M., Berg, E., Hummel, M., Rau, B., Stein, U., Treese, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Brief Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577914/ https://www.ncbi.nlm.nih.gov/pubmed/32488802 http://dx.doi.org/10.1007/s12094-020-02380-0

Ejemplares similares

Prognostic impact of activin subunit inhibin beta A in gastric and esophageal adenocarcinomas
por: Staudacher, J. J., et al.
Publicado: (2022)

Inhibition of MACC1-Induced Metastasis in Esophageal and Gastric Adenocarcinomas
por: Treese, Christoph, et al.
Publicado: (2022)

Prognostic value of claudin 18.2 expression in gastric adenocarcinoma
por: Kayikcioglu, Erkan, et al.
Publicado: (2023)

Better prognosis of gastric cancer patients with high levels of tumor infiltrating lymphocytes is counteracted by PD-1 expression
por: Pötzsch, M., et al.
Publicado: (2020)

S100A4 Is a Strong Negative Prognostic Marker and Potential Therapeutic Target in Adenocarcinoma of the Stomach and Esophagus
por: Treese, Christoph, et al.
Publicado: (2022)

Claudin 18.2 expression in esophageal adenocarcinoma and its potential impact on future treatment strategies
por: Moentenich, Valeska, et al.
Publicado: (2020)

Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas
por: Klempner, S.J., et al.
Publicado: (2023)

Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody
por: Bähr-Mahmud, Hayat, et al.
Publicado: (2023)

Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer
por: Kim, Hyung-Don, et al.
Publicado: (2023)

Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma
por: Rohde, Christoph, et al.
Publicado: (2019)

Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer
por: Zhang, Jianwei, et al.
Publicado: (2020)

Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer
por: Xu, Bo, et al.
Publicado: (2022)

Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma
por: Wang, Xi, et al.
Publicado: (2022)

Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
por: Singh, Prabhsimranjot, et al.
Publicado: (2017)

Clinicopathologic Relevance of Claudin 18.2 Expression in Gastric Cancer: A Meta-Analysis
por: Ungureanu, Bogdan Silviu, et al.
Publicado: (2021)

ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma
por: Klempner, Samuel J., et al.
Publicado: (2023)

The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes
por: Kayikcioglu, Erkan, et al.
Publicado: (2023)

Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer
por: Kubota, Y., et al.
Publicado: (2023)

Poorly Differentiated Medullary Phenotype Predicts Poor Survival in Early Lymph Node-Negative Gastro-Esophageal Adenocarcinomas
por: Treese, Christoph, et al.
Publicado: (2016)

Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy
por: Cao, Weijie, et al.
Publicado: (2022)

Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer
por: Hong, Jung Yong, et al.
Publicado: (2020)

Frequency of Positive Familial Criteria in Patients with Adenocarcinoma of the Esophageal-Gastric Junction and Stomach: First Prospective Data in a Caucasian Cohort †
por: Schölzchen, Jan, et al.
Publicado: (2022)

CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer
por: Qi, Changsong, et al.
Publicado: (2023)

Development and comparison of (68)Ga/(18)F/(64)Cu-labeled nanobody tracers probing Claudin18.2
por: Wei, Weijun, et al.
Publicado: (2022)

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
por: Qi, Changsong, et al.
Publicado: (2022)

Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers
por: Zhong, Weixiang, et al.
Publicado: (2022)

Immunoexpression of Claudin 4 in Gastric Adenocarcinomas
por: CREȚU, OANA IULIA, et al.
Publicado: (2022)

Response prediction in patients with gastric and esophagogastric adenocarcinoma under neoadjuvant chemotherapy using targeted gene expression analysis and next-generation sequencing in pre-therapeutic biopsies
por: Kleo, Karsten, et al.
Publicado: (2022)

Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study
por: Dottermusch, Matthias, et al.
Publicado: (2019)

Claudin18.2 bispecific T cell engager armed oncolytic virus enhances antitumor effects against pancreatic cancer
por: Liu, Shiyu, et al.
Publicado: (2023)

Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma
por: Shitara, Kohei, et al.
Publicado: (2022)

Case Report: A rare case of recurrent ascites after anti-Claudin18.2 antibody therapy for metastatic gastric cancer while responding sustainingly
por: Liu, Jinlu, et al.
Publicado: (2023)

IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models
por: Shi, Hongtai, et al.
Publicado: (2023)

Hereditary Diffuse Gastric Cancer—Update Based on the Current Consort Recommendations
por: Treese, Christoph, et al.
Publicado: (2022)

FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer
por: Liu, Yifan, et al.
Publicado: (2023)

Prognostic Significance of Claudin 4 in Completely Resected Adenocarcinoma of the Lung
por: Chae, Min Cheol, et al.
Publicado: (2014)

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
por: Shah, Manish A., et al.
Publicado: (2023)

Methylation of the claudin-3 promoter predicts the prognosis of advanced gastric adenocarcinoma
por: Zhang, Zhenzhen, et al.
Publicado: (2018)

Immunoexpression of E-cadherin, CD44 and Claudin 7 in gastric adenocarcinomas
por: Creţu, Oana Iulia, et al.
Publicado: (2022)

Claudin-18 expression in small bowel adenocarcinoma: a clinico-pathologic study
por: Arpa, Giovanni, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ufqgs30dkoqnvuc2ccjgdr0q3v